The impact of gut microbiota on insulin resistance in polycystic ovary syndrome: mechanisms and therapeutic prospects
Abstract
Polycystic ovary syndrome (PCOS) is a prevalent endocrine and metabolic disorder, with insulin resistance (IR) serving as its core pathophysiological feature and a key driver of long-term metabolic complications. Recent studies have revealed that the gut microbiota, as a critical environmental factor, plays a significant role in the pathogenesis of PCOS. The gut microbiota profoundly engages in the pathophysiology of PCOS-IR through multiple pathways and networked interactions. This review provides a comprehensive narrative synthesis of the latest evidence on gut microbiota dysbiosis in PCOS-IR, with a particular focus on its molecular mechanisms, and evaluates therapeutic strategies based on gut microbiota modulation. It seeks to provide theoretical foundations and forward-looking perspectives for precision microbiome therapies. Importantly, this is a narrative review with a mechanistic focus, rather than a formal systematic review or meta-analysis.
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.